APPLICATION OF "L-BIOCOMPLEX" IN CHRONIC HEART FAILURE TREATMENT IN PATIENTS WITH METABOLIC SYNDROME

The combination of chronic heart failure and metabolic syndrome is a common clinical case. Patients with this pathology belong to the group high cardiovascular risk, which explained by higher frequency severity traditional factors. Of particular interest use "L−BIOCOMPLEX (liposomal)" dietary supplement "Biolik" company (Kharkiv, Ukraine), available in liposomal form as set L−carnitine + thioctic acid pathology. To study its effect on treatment efficiency, 40 patients were examined. result for whose complex included "L−BIOCOMPLEX" at dose 5 ml 10 once day 30 minutes before meals four weeks, those receiving only basic therapy. It has been shown that L−BIOCOMPLEX an additive standard therapy improves functional state patients: reduces class failure, increases exercise tolerance, enhances diastolic function boosts left ventricular ejection fraction ventricle. inclusion scheme helped improve quality life patients. As part positively affects lipid carbohydrate metabolism, atherogenic lipids, diminishes insulin resistance. Thus, positive influence additional risk factors, affecting prognosis playing significant role mechanisms development progression failure. Key words: "L−BIOCOMPLEX", L−carnitine, acid, syndrome.